These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 20677568

  • 1. [The predictive value of EGFR status in non-small cell lung cancer patients treated with EGFR-TKIs].
    Wang Y, Liu H, Chen J.
    Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):375-9. PubMed ID: 20677568
    [Abstract] [Full Text] [Related]

  • 2. Lifestyle risks exposure and response predictor of gefitinib in patients with non-small cell lung cancer.
    Ying H, Yang XD, Sun Z, Ning X, Wang Y, Bai C, Chen S, Wang Y.
    Med Oncol; 2014 Oct; 31(10):220. PubMed ID: 25216867
    [Abstract] [Full Text] [Related]

  • 3. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
    Lee JK, Shin JY, Kim S, Lee S, Park C, Kim JY, Koh Y, Keam B, Min HS, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS, Lee SH, Kim JI.
    Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152
    [Abstract] [Full Text] [Related]

  • 4. Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).
    Martínez-Navarro EM, Rebollo J, González-Manzano R, Sureda M, Evgenyeva E, Valenzuela B, Fernández FJ, Forteza J, Brugarolas A.
    Clin Transl Oncol; 2011 Nov; 13(11):812-8. PubMed ID: 22082647
    [Abstract] [Full Text] [Related]

  • 5. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
    Nguyen KS, Kobayashi S, Costa DB.
    Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC, Lim CK, Chang LY, Chen KY, Shih JY, Yu CJ.
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [Abstract] [Full Text] [Related]

  • 9. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
    Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, Huberman MS, Cohen DW, Nakayama S, Ishioka K, Yamaguchi N, Hanna M, Oxnard GR, Lathan CS, Moran T, Sequist LV, Chaft JE, Riely GJ, Arcila ME, Soo RA, Meyerson M, Eck MJ, Kobayashi SS, Costa DB.
    Sci Transl Med; 2013 Dec 18; 5(216):216ra177. PubMed ID: 24353160
    [Abstract] [Full Text] [Related]

  • 10. Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?
    Tartarone A, Lerose R, Lazzari C, Gregorc V, Aieta M.
    Med Oncol; 2014 Aug 18; 31(8):78. PubMed ID: 24958518
    [Abstract] [Full Text] [Related]

  • 11. Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations.
    Lin CC, Yang JC.
    Drugs; 2011 Jan 01; 71(1):79-88. PubMed ID: 21175241
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer.
    van Zandwijk N, Mathy A, Boerrigter L, Ruijter H, Tielen I, de Jong D, Baas P, Burgers S, Nederlof P.
    Ann Oncol; 2007 Jan 01; 18(1):99-103. PubMed ID: 17060486
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
    Sohn HS, Kwon JW, Shin S, Kim HS, Kim H.
    J Clin Pharm Ther; 2015 Dec 01; 40(6):661-71. PubMed ID: 26573867
    [Abstract] [Full Text] [Related]

  • 17. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
    Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Jänne PA, Lynch T, Johnson BE, Miller VA.
    J Clin Oncol; 2010 Jan 10; 28(2):357-60. PubMed ID: 19949011
    [Abstract] [Full Text] [Related]

  • 18. Comparing the effectiveness of different EGFR-TKIs in patients with EGFR mutant non-small-cell lung cancer: A retrospective cohort study in Taiwan.
    Hsieh YY, Fang WT, Lo YW, Chen YH, Chien LN.
    Int J Cancer; 2020 Aug 15; 147(4):1107-1116. PubMed ID: 31854456
    [Abstract] [Full Text] [Related]

  • 19. Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer.
    Kosaka T, Yamaki E, Mogi A, Kuwano H.
    J Biomed Biotechnol; 2011 Aug 15; 2011():165214. PubMed ID: 21687596
    [Abstract] [Full Text] [Related]

  • 20. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA.
    Cochrane Database Syst Rev; 2016 May 25; (5):CD010383. PubMed ID: 27223332
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.